Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 9/20 | 0.46 |
| ▸ | NOS2 | P35228 | 9/20 | 0.46 |
| ▸ | NOS1 | P29475 | 6/20 | 0.46 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | CCR8 | P51685 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | USP7 | Q93009 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11714628 | 0.81 | NOS3 (0.40) | NOS3NOS2NOS1UHRF1USP7 | |
| SCHEMBL2482691 | 0.81 | NOS3 (0.48) | NOS3NOS2NOS1UHRF1CCR1 | |
| SCHEMBL5809638 | 0.79 | NOS3 (0.46) | NOS3NOS2NOS1UHRF1CCR1 | |
| SCHEMBL23556108 | 0.78 | DYRK1A (0.37) | NOS3NOS2NOS1USP7ALDH1A1 | |
| SCHEMBL24033512 | 0.78 | HTT (0.41) | NOS3NOS2NOS1UHRF1MAP4K4 | |
| SCHEMBL31041294 | 0.78 | HTT (0.41) | NOS3NOS2NOS1UHRF1MAP4K4 | |
| Ammonia Solution, Strong SCHEMBL29016866 | 0.77 | NOS3 (0.44) | NOS3NOS2NOS1UHRF1CCR1 | |
| SCHEMBL26359987 | 0.76 | CCR1 (0.37) | NOS3NOS2NOS1CCR1CCR5 | |
| SCHEMBL22809671 | 0.75 | NOS3 (0.38) | NOS3NOS2NOS1USP7 | |
| SCHEMBL2222027 | 0.75 | NOS3 (0.38) | NOS3NOS2NOS1USP7RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200148693-A1 | Chemical Compounds | AVISTA PHARMA SOLUTIONS INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-20200148693-A1 | Chemical Compounds | AVISTA PHARMA SOLUTIONS INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10570144-B2 | Substituted ureas as prostaglandin EP4 receptor antagonists | AVISTA PHARMA SOLUTIONS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10570144-B2 | Substituted ureas as prostaglandin EP4 receptor antagonists | AVISTA PHARMA SOLUTIONS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10239885-B1 | Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist | AVISTA PHARMA SOLUTIONS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10239885-B1 | Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist | AVISTA PHARMA SOLUTIONS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148693-A1 | Chemical Compounds | PTGER4, PTGES, PTGER1 | NOS3 410/4885NOS2 451/4885NOS1 856/4885 |
| US-10239885-B1 | Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist | PTGER4, PTGER1, PTGER2 | NOS3 707/4885NOS2 606/4885NOS1 970/4885 |
| US-10570144-B2 | Substituted ureas as prostaglandin EP4 receptor antagonists | PTGER4, PTGER1, PTGER2 | NOS3 295/4885NOS2 217/4885NOS1 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.